Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Gaush Meditech Ltd

高视医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2407)

VOLUNTARY ANNOUNCEMENT ASPHERIC INTRAOCULAR LENS OBTAINED NMPA MEDICAL DEVICE REGISTRATION CERTIFICATE

This announcement is made by Gaush Meditech Ltd (the "Company", together with its subsidiaries, the "Group") on a voluntary basis, to inform the shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the "Board") of directors (the "Director(s)") of the Company is pleased to announce that, on May 17, 2024, the aspheric intraocular lens of Gaush Teleon Ltd* (高視 泰靚醫療科技有限公司) ("Gaush Teleon"), a wholly-owned subsidiary of the Company, has obtained the medical device registration certificate issued by the National Medical Products Administration (NMPA) of the People's Republic of China ("China"), nearly two quarters ahead of schedule. As of the date of this announcement, Gaush Teleon has obtained medical device registration certificates for two intraocular lenses. This achievement further enriches the localized intraocular lens product line of the Company, and signifies the further consolidation of Gaush Teleon's research and development and the overall process and production capability of intraocular lenses.

Cataract is a relatively serious eye disorder and the biggest cause of blindness worldwide. According to the Chinese Guideline for Cataract Surgery in Adults (《中國成人白內障摘除手術指南》) and other expert consensus, currently the effective treatment for restoring vision of patients is surgical intervention. This procedure involves the removal of the clouded lens and the implantation of intraocular lens to enhance the patient's vision. Given the large population base and the increasing aging population in China, the number of cataract patients has been increasing continuously. According to the statistics of the Chinese Ophthalmological Society, the incidence of cataracts among individuals aged 60 to 89 in China is 80%, rising to over 90% for those aged 90 and above. Currently, China is rapidly transitioning into an aging society. In 2023, the population aged 60 and above reached 297 million, representing 21.1% of the total population, while those aged 65 and above reached 217 million, representing 15.4% of the total population.

The approved aspheric intraocular lens (registration number: Guo Xie Zhu Zhun (國械注 淮) 20243160955) of Gaush Teleon uses the patented HydroSmart material that combines the advantages of hydrophobicity and hydrophilicity and adopts the classic C-loop design, zero spherical aberration design, and 360° continuous rear surface right-angled square-edge design, which is highly inclusive and can bring clear and stable vision quality to the cataract patients after the surgical implantation. The product has also been registered as an approved imported medical device (registration number: Guo Xie Zhu Jin (國械注進) 20173162080) and successfully transitioned to being manufactured within China, achieving the localization of the same product quality.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Gaush Meditech Ltd
Mr. Gao Tieta
Chairman and Executive Director

Hong Kong, May 29, 2024

As of the date of this announcement, the Board comprises Mr. Gao Tieta as Chairman and executive Director, Mr. Liu Xinwei, Mr. Zhao Xinli, Mr. Zhang Jianjun and Ms. Li Wenqi as executive Directors, Dr. David Guowei Wang as non-executive Director, and Mr. Feng Xin, Mr. Wang Li-Shin and Mr. Chan Fan Shing as independent non-executive Directors.

* For identification purposes only